Noorian Sepideh, Mottaghi-Dastjerdi Negar, Soltany-Rezaee-Rad Mohammad, Montazeri Hamed, Baghaei Masoumeh, Niazi Mohammad-Javad
Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran.
Behestan Innovation Factory, Tehran, Iran.
Iran J Pharm Res. 2024 Sep 11;23(1):e146572. doi: 10.5812/ijpr-146572. eCollection 2024 Jan-Dec.
Despite the availability of tetanus-diphtheria (TD) vaccines in Iran, the seroconversion rate of these products as a booster dose is unknown.
This study evaluates the seroconversion rate of the Iranian Td vaccine in adults who have not been vaccinated in the past decade.
In this study, 20 adult volunteers aged 18 to 60 who had not received the Td vaccine in the past decade received a booster dose of the Iranian Td vaccine. Twenty-eight days after vaccination, the seroconversion rate was evaluated using the ELISA method. Vaccine adverse events were monitored at three time points after vaccination.
Seroconversion rates with the Iranian Td vaccine boosters were 75% and 90%, respectively, based on a 4-fold increase in anti-tetanus toxoid antibody titers and a 2- and 4-fold combination. Significant associations were found between the demographic data, specifically female gender and age 43 years and older, with seroconversion rates. Injection-site pain was the most common adverse reaction, with a frequency of 35%. No adverse events were reported between one week and one month after vaccination.
Results showed that a booster dose of the Iranian Td vaccine produced a protective titer (> 0.1 IU/mL) and a long-term protective titer (> 1.0 IU/mL) in 100% of participants. The seroconversion rate of the Iranian Td vaccine was comparable to other common tetanus vaccines, including Tenivac, Adacel, Infanrix, Tetavax, and Vacteta. The proportion of suitable candidates for plasma donation, based on minimum (2 IU/mL) and maximum (10 IU/mL) anti-tetanus toxoid antibody titers, was 100% and 45%, respectively.
尽管伊朗有破伤风-白喉（TD）疫苗，但这些产品作为加强剂量的血清转化率尚不清楚。
本研究评估伊朗Td疫苗在过去十年未接种疫苗的成年人中的血清转化率。
在本研究中，20名年龄在18至60岁之间、过去十年未接种Td疫苗的成年志愿者接受了一剂伊朗Td疫苗加强针。接种疫苗28天后，采用酶联免疫吸附测定（ELISA）法评估血清转化率。在接种疫苗后的三个时间点监测疫苗不良事件。
根据抗破伤风类毒素抗体滴度4倍升高以及2倍和4倍升高的组合，伊朗Td疫苗加强针的血清转化率分别为75%和90%。在人口统计学数据，特别是女性性别以及43岁及以上年龄与血清转化率之间发现了显著关联。注射部位疼痛是最常见的不良反应，发生率为35%。接种疫苗后一周至一个月期间未报告不良事件。
结果表明，一剂伊朗Td疫苗加强针在100%的参与者中产生了保护性滴度（>0.1 IU/mL）和长期保护性滴度（>1.0 IU/mL）。伊朗Td疫苗的血清转化率与其他常见破伤风疫苗相当，包括Tenivac、Adacel、Infanrix、Tetavax和Vacteta。根据最低（2 IU/mL）和最高（10 IU/mL）抗破伤风类毒素抗体滴度，适合献血浆的候选者比例分别为100%和45%。
